Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.
加利福尼亞州諾瓦託，2025年1月6日（全球新聞稿）——Ultragenyx Pharmaceutical Inc.（納斯達克：RARE），一家專注於開發和商業化用於治療嚴重稀有和超稀有遺傳疾病的新療法的生物製藥公司，今天宣佈公司首席執行官兼總裁Emil D. Kakkis萬.D.，博士，將於2025年1月13日（星期一）上午10:30（太平洋時間）在第43屆J.P. 摩根醫療保健會議上發表演講。
The live and archived webcast of the presentation will be accessible from the company's website at . The replay of the webcast will be available for 30 days.
演示的現場直播和歸檔網絡廣播將可從公司網站訪問。該網絡廣播的重播將可以在30天內觀看。
About Ultragenyx Pharmaceutical Inc.
關於Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx是一家生物製藥公司，致力於爲患者提供新型產品，以治療嚴重的罕見和超罕見遺傳疾病。該公司建立了一個多樣化的已批准療法和產品候選者組合，旨在解決具有高未滿足醫療需求和明確治療生物的疾病，通常這些疾病沒有批准的療法來治療其根本原因。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
該公司由一支有豐富罕見病治療藥物開發和商業化經驗的管理團隊領導。Ultragenyx 的策略基於及時高效的藥品研發，旨在以最大的緊迫性向患者提供安全有效的治療。
For more information on Ultragenyx, please visit the company's website at: .
欲了解更多有關Ultragenyx的信息，請訪問公司的官方網站：。
Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
聯繫 - Ultragenyx Pharmaceutical, Inc.
投資者
Joshua Higa
ir@ultragenyx.com
譯文內容由第三人軟體翻譯。